To include your compound in the COVID-19 Resource Center, submit it here.

Following Phase III readout, Karyopharm seeks approval of Xpovio for second-line MM

Karyopharm gained $11.38 (70%) to $27.72 on Monday, adding about $746 million in market value, after announcing that Xpovio selinexor met the primary endpoint of improving PFS in the confirmatory Phase III BOSTON trial to treat multiple myeloma. The addition of Xpovio to standard-of-care Velcade and dexamethasone also reduced peripheral neuropathy vs. SOC alone, suggesting a safety

Read the full 579 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers